10/17/2025
Living with eczema is more than a skin condition—it’s an ongoing journey filled with defining moments of courage, clarity, and care. Whether you’re managing burdensome symptoms like itch, advocating for effective treatment, or simply seeking support - you’re not alone.
Join us on Tuesday, October 28 for a conversation that will inspire and empower. Here's what you can expect:
🧠Expert insights from leading voices in eczema care
💡Tips and tools for managing symptoms & self-advocacy
💬Candid personal stories from a dermatologist, comedian, and advocate
When: Tuesday, October 28 | 5:30–7:30 PM ET
Where: 475 5th Ave, New York, NY
Reserve your spot today—spaces are limited! https://events.shemedia.com/Empowered-With-The-Skin-Youre-In
Sponsored by Incyte
INDICATION & USAGE
IMPORTANT SAFETY INFORMATION
OPZELURA is a prescription medicine used on the skin (topical) for the short-term and non-continuous chronic treatment of mild to moderate eczema in non-immunocompromised adults and children 12 years of age and older whose disease is not well controlled with topical prescription therapies or when those therapies are not recommended.
The use of OPZELURA along with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants such as azathioprine or cyclosporine is not recommended.
It is not known if OPZELURA is safe and effective in children less than 12 years of age with atopic dermatitis.
SELECT SAFETY INFO
OPZELURA may cause serious side effects, including:
Serious Infections: OPZELURA is in a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors can lower your ability to fight infections. Serious infections, some fatal, occurred when taking JAK inhibitors by mouth including tuberculosis and infections caused by bacteria, fungi, or viruses. Some lung infections were seen in people using OPZELURA.
Before starting OPZELURA, tell your healthcare provider if you: have an infection (ie fever, sweating, chills), have diabetes, lung disease, HIV, or a weak immune system.
Increased risk of death in people age 50+ with at least one heart disease risk factor when taking JAK inhibitors by mouth.
Cancer and immune system problems: OPZELURA may increase your risk of certain cancers (lymphoma, lung, and skin) by changing the way your immune system works. Tell your doctor if you have had any type of cancer.
Increased risk of major cardiovascular events such as heart attack, stroke, or death in people 50+ with at least one heart disease risk factor when taking JAK inhibitors by mouth, especially in current or past smokers.
Blood clots: Blood clots in veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) can happen. This may be life-threatening. These types of blood clots occurred more often in people 50+ with at least one heart disease risk factor when taking JAK inhibitors by mouth.
OPZELURA and the OPZELURA logo are registered trademarks of Incyte.
©2025, Incyte. MAT-OPZ-03363 09/25
